Research Topics
Species | THOMAS DAVID GILMORESummaryAffiliation: Boston University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
The Re1/NF-kappa B/I kappa B signal transduction pathway and cancerThomas D Gilmore
Biology Department, Boston University, Boston, MA, USA
Cancer Treat Res 115:241-65. 2003
A report from the second Nematostella vectensis research conferenceThomas D Gilmore
Department of Biology, Boston University, 5 Cummington Mall, Boston, MA, 02215, USA
Dev Genes Evol 223:207-11. 2013..In addition, research was presented on the use of Nematostella in developmental, regeneration, signal transduction, host-symbiont, and gene-environment interaction studies...- NF-κB: where did it come from and why?Thomas D Gilmore
Department of Biology, Boston University, Boston, MA 02215, USA
Immunol Rev 246:14-35. 2012.... - Inhibition of NF-κB signaling as a strategy in disease therapyThomas D Gilmore
Biology Department, Boston University, 5 Cummington Street, Boston, MA 02215, USA
Curr Top Microbiol Immunol 349:245-63. 2011..Finally, the rationale and strategies for inhibiting specific NF-κB subunit activity for disease therapy are discussed... - Multiple myeloma: lusting for NF-kappaBThomas D Gilmore
Department of Biology, Boston University, Boston, MA 02215, USA
Cancer Cell 12:95-7. 2007..These results reveal the molecular basis for constitutive NF-kappaB activity in many MMs and further validate the NF-kappaB signaling pathway as an appropriate target for MM therapy... - Inhibitors of NF-kappaB signaling: 785 and countingT D Gilmore
Biology Department, Boston University, Boston, MA 02215, USA
Oncogene 25:6887-99. 2006..Moreover, the therapeutic and preventative effects of many natural products may, at least in part, be due to their ability to inhibit NF-kappaB... - Introduction to NF-kappaB: players, pathways, perspectivesT D Gilmore
Biology Department, Boston University, Boston, MA 02215, USA
Oncogene 25:6680-4. 2006..The organization and focus of articles included in the following reviews are described, as well as likely future areas of research interest on NF-kappaB... - Malignant transformation of primary chicken spleen cells by human transcription factor c-RelT D Gilmore
Department of Biology, Boston University, 5 Cummington Street, Boston, Massachusetts, MA 02215, USA
Oncogene 20:7098-103. 2001..These results are the first demonstration of a lymphoid cell malignant transforming ability for mammalian Rel/NF-kappaB transcription factors, and implicate c-Rel as a molecular target for cancer therapeutics... - The c-Rel transcription factor and B-cell proliferation: a deal with the devilThomas D Gilmore
Department of Biology, Boston University, 5 Cummington Street, Boston, MA 02215, USA
Oncogene 23:2275-86. 2004..In any event, REL may provide an appropriate therapeutic target for certain human lymphoid cell malignancies... - Stable expression of the avian retroviral oncoprotein v-Rel in avian, mouse, and dog cell linesThomas D Gilmore
Biology Department, Boston University, 5 Cummington Street, Boston, MA 02215, USA
Virology 316:9-16. 2003..The findings reported here are an essential first step in the development of mammalian systems to study Rel-mediated oncogenesis... - Rel/NF-kappa B/I kappa B signal transduction in the generation and treatment of human cancerThomas Gilmore
Department of Biology, Boston University, 5 Cummington Street, Boston, MA 02215, USA
Cancer Lett 181:1-9. 2002..In many cases, inhibition of Rel/NF-kappa B activity reverses all or part of the malignant state. Thus, the Rel/NF-kappa B pathway has received much attention as a focal point for clinical intervention... - Immortalized embryonic mouse fibroblasts lacking the RelA subunit of transcription factor NF-kappaB have a malignantly transformed phenotypeMaria-Emily R Gapuzan
Biology Department, Boston University, 5 Cummington Street, Boston, MA 02215, USA
Oncogene 21:2484-92. 2002..Taken together, these results suggest that RelA has tumor suppressing activity under some circumstances and that RelA complexes are involved in the control of a variety of cellular properties associated with oncogenesis... 
Histone acetyltransferase p300 is a coactivator for transcription factor REL and is C-terminally truncated in the human diffuse large B-cell lymphoma cell line RC-K8Michael R Garbati
Department of Biology, Boston University, Boston, MA 02215, USA
Cancer Lett 291:237-45. 2010..However, due to a deletion in the EP300 locus, only a C-terminally truncated form of p300 is expressed in RC-K8 cells. These results suggest a role for p300 in REL-mediated oncogenic activity in B lymphoma...- Deletion of either C-terminal transactivation subdomain enhances the in vitro transforming activity of human transcription factor REL in chicken spleen cellsDaniel T Starczynowski
Department of Biology, Boston University, 5 Cummington Street, Boston, MA 02215, USA
Oncogene 22:6928-36. 2003.... - Immortalized fibroblasts from NF-kappaB RelA knockout mice show phenotypic heterogeneity and maintain increased sensitivity to tumor necrosis factor alpha after transformation by v-RasMaria-Emily R Gapuzan
Department of Biology, Boston University, 5 Cummington Street, Boston, MA 02215, USA
Oncogene 24:6574-83. 2005..These results suggest that RelA is a potential protein target for human tumors driven by oncogenic Ras mutations, but caution that inhibition of RelA may promote tumorigenesis in some circumstances... - Ser484 and Ser494 in REL are the major sites of IKK phosphorylation in vitro: evidence that IKK does not directly enhance GAL4-REL transactivationMichael R Garbati
Department of Biology, Boston University, 5 Cummington Street, Boston, MA 02215, USA
Gene Expr 14:195-205. 2008..Taken together, these results do not support a role for IKK-mediated phosphorylation as means for regulating the activity of REL in vivo... - Characterization of a human REL-estrogen receptor fusion protein with a reverse conditional transforming activity in chicken spleen cellsDemetrios Kalaitzidis
Department of Biology, Boston University, 5 Cummington Street, MA 02215, USA
Oncogene 23:7580-7. 2004.... - Mutations of tumor necrosis factor alpha-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL enhance its in vitro transforming abilityDaniel T Starczynowski
Department of Biology, Boston University, 5 Cummington Street, Boston, MA 02215, USA
Oncogene 24:7355-68. 2005..Lastly, these results suggest that similar mutations in the REL transactivation domain contribute to the development of certain human B-cell lymphomas... - The synthetic epoxyquinoids jesterone dimer and epoxyquinone A monomer induce apoptosis and inhibit REL (human c-Rel) DNA binding in an IkappaBalpha-deficient diffuse large B-cell lymphoma cell lineMei-Chih Liang
Department of Biology, Boston University, 5 Cummington Street, Boston, MA 02215, USA
Cancer Lett 241:69-78. 2006..These results suggest that JD and EqM can induce apoptosis in IkappaBalpha-deficient lymphoma cells through a mechanism involving direct inhibition of transcription factor REL... - The human B-cell lymphoma cell line RC-K8 has multiple genetic alterations that dysregulate the Rel/NF-kappaB signal transduction pathwayDemetrios Kalaitzidis
Department of Biology, Boston University, 5 Cummington Street, Boston, Massachusetts, MA 02215, USA
Oncogene 21:8759-68. 2002..Nevertheless, the RC-K8 cell line is the first tumor cell line identified with mutations in genes encoding multiple proteins in the Rel/NF-kappaB signal transduction pathway... - Rel homology domain-containing transcription factors in the cnidarian Nematostella vectensisJames C Sullivan
Department of Biology, Boston University, 5 Cummington Street, Boston, MA 02215, USA
Dev Genes Evol 217:63-72. 2007.... - Mutations within a conserved protein kinase A recognition sequence confer temperature-sensitive and partially defective activities onto mouse c-RelMaria Emily R Gapuzan
Biology Department, Boston University, 5 Cummington Street, Boston, MA 02215 2406, USA
Biochem Biophys Res Commun 307:92-9. 2003..Conditional and partially defective mutants such as those described herein may be useful for identifying physiological responses and genes regulated by specific Rel/NF-kappaB family members... - Jesterone dimer, a synthetic derivative of the fungal metabolite jesterone, blocks activation of transcription factor nuclear factor kappaB by inhibiting the inhibitor of kappaB kinaseMei-Chih Liang
Department of Biology, Boston University, Boston, Massachusetts, USA
Mol Pharmacol 64:123-31. 2003.... - Characterization of the core elements of the NF-κB signaling pathway of the sea anemone Nematostella vectensisFrancis S Wolenski
Department of Biology, Boston University, 5 Cummington Street, Boston, MA 02215, USA
Mol Cell Biol 31:1076-87. 2011..These results indicate that NF-κB pathway proteins in Nematostella are similar to their vertebrate homologs, and these results also provide a framework for understanding the evolutionary origins of NF-κB signaling... - Genomic organization and expression of the rearranged REL proto-oncogene in the human B-cell lymphoma cell line RC-K8Demetrios Kalaitzidis
Department of Biology, Boston University, Boston, Massachusetts 02215, USA
Genes Chromosomes Cancer 34:129-35. 2002..Furthermore, like c-Rel, c-Rel-Nrg is a cytoplasmic protein when overexpressed in fibroblasts in culture and can bind to a kappaB DNA site in vitro... - Two alleles of NF-kappaB in the sea anemone Nematostella vectensis are widely dispersed in nature and encode proteins with distinct activitiesJames C Sullivan
Department of Biology, Boston University, Boston, Massachusetts, United States of America
PLoS ONE 4:e7311. 2009..NF-kappaB proteins contain a highly conserved DNA-binding/dimerization domain called the Rel homology domain... - Alternative splicing in the NF-kappaB signaling pathwayJoshua R Leeman
Department of Biology, Boston University, 5 Cummington Street, Boston, MA 02215, USA
Gene 423:97-107. 2008..Moreover, some NF-kappaB alternative splicing events appear to be specific for certain diseases, and could serve as therapeutic targets or biomarkers... - Angiogenesis inhibitor epoxyquinol a: total synthesis and inhibition of transcription factor NF-kappaBChaomin Li
Department of Chemistry and Center for Streamlined Synthesis, Boston University, Massachusetts 02215, USA
Org Lett 4:3267-70. 2002..In addition, we show that 1 and related molecules inhibit activation of the transcription factor NF-kappaB... - Inhibition of transcription factor NF-kappaB signaling proteins IKKbeta and p65 through specific cysteine residues by epoxyquinone A monomer: correlation with its anti-cancer cell growth activityMei-Chih Liang
Department of Biology, Boston University, 5 Cummington Street, Boston, MA 02215, USA
Biochem Pharmacol 71:634-45. 2006..Taken together, these results suggest that EqM inhibits growth and induces cell death in tumor cells through a mechanism that involves inhibition of NF-kappaB activity at multiple steps in the signaling pathway... - Transcription factor cross-talk: the estrogen receptor and NF-kappaBDemetrios Kalaitzidis
Boston University, Department of Biology, 5 Cummington Street, Boston, MA 02215, USA
Trends Endocrinol Metab 16:46-52. 2005..Such cross-talk between these important regulators of the endocrine and immune systems might be exploited for the treatment of cancer and inflammatory and autoimmune diseases...
Research Grants
- TRANSFORMATION OF CELLS BY THE V-REL ONCOGENEThomas Gilmore; Fiscal Year: 1999..Together, these experiments will serve as models for understanding the molecular mechanisms underlying the development of a subset of human lymphoid malignancies. ..
- Transformation of Cells by the REL OncogeneThomas Gilmore; Fiscal Year: 2007....
- TRANSFORMATION OF CELLS BY THE V REL ONCOGENEThomas Gilmore; Fiscal Year: 2003..A long-term goal of this project will be to develop mammalian model systems for studying Rel-mediated oncogenesis, in order to more closely mimic human cancers that involve alterations in Rel transcription factor function. ..
- Transformation of Cells by the REL OncogeneThomas Gilmore; Fiscal Year: 2009....